Atea Pharmaceuticals, Inc. income statement

In fiscal 2021, Atea Pharmaceuticals, Inc. reported revenue of $351m, up 622.5% on the year before, operating income of $138m (a 39.4% margin) and net income of $121m, or $1.37 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atea Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021
Revenue	49	351
Research and development	38	167
General and administrative	22	46
Operating income	−11	138
Income before tax	−11	139
Income tax	—	17
Net income	−11	121
Diluted EPS	−$0.13	$1.37
Diluted shares (average)	86m	88m
EBITDA	−11	138

US$ millions unless shown otherwise. Fiscal quarters.

Atea Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021
Revenue	66	60	33	192
Research and development	27	40	43	58
General and administrative	9	12	12	13
Operating income	31	9	−22	121
Income before tax	31	9	−22	121
Income tax	—	7	6	4
Net income	31	2	−28	117
Diluted EPS	$0.34	$0.02	−$0.34	$1.32
EBITDA	31	9	−22	121

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atea Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atea Pharmaceuticals, Inc.